Multiple sclerosis outcomes after cancer immunotherapy.
Catherine R GarciaRani JayswalVal AdamsLowell B AnthonyJohn L VillanoPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2019)
Reported MS relapses after ICI are rare, but the adverse events described include rapid neurologic progression and death. Larger and prospective studies are warranted to assess disability and long-term outcomes and outweigh the risks of starting immunotherapy in patients with MS.